Nuclear Weekly Notable Price Action
1/31/26
SEQH CAPITAL RESEARCH
Nuclear & Uranium Weekly
Top 5 Notable Price Action – Week Ending Jan 31, 2026
Sector Backdrop
Uranium spot pushed through the US$100/lb level to fresh 23‑month highs as physical availability tightened and financial vehicles continued to remove material from the market.
Policy tone stayed supportive: Trump’s pro‑nuclear messaging out of Davos and ongoing rulebook streamlining for advanced reactors reinforced a more permissive regulatory regime.
Despite this, uranium equities chopped sideways to lower late in the week as investors locked in strong January gains; several leaders finished the week modestly down from recent highs.
Against that backdrop, these five watchlist names offered the most relevant mix of news and price action.
1. NexGen Energy (NXE)
Weekly action (US‑listing):
NXE traded down modestly on the week, slipping from the low‑$13s to the mid‑$12s despite briefly hitting a new 52‑week high on the Canadian line earlier in the week.
What drove trading
On the TSX, NexGen printed an intraday high of C$18.04 on heavy volume as the market continued to price in a favorable licensing outcome for Rook I.
Multiple brokers reiterated or raised price targets into the move, reinforcing the “best‑in‑class Athabasca developer” narrative.
As the week progressed, the stock faded with the broader uranium group on profit‑taking and risk‑off flows despite no negative company‑specific news.
Why we remain bullish
Rook I remains one of the few globally significant, low‑cost, high‑grade projects capable of moving the needle on the structural supply deficit.
A positive Canadian Nuclear Safety Commission decision (expected near term) is a clear re‑rating catalyst and de‑risks the path to construction.
NexGen’s balance sheet, Athabasca footprint, and community partnerships provide both financial and social‑license runway that many peers lack.
2. ASP Isotopes (ASPI)
Weekly action:
ASPI was volatile but ended the week lower versus the prior Friday, after spiking mid‑week and then selling off sharply on the sector down‑day.
What drove trading
Earlier in January, ASPI shares jumped over 10% in a single session on increasing speculative interest.
This past week, the company provided a detailed production update on the Renergen helium project, highlighting:
Progress on drilling and plant readiness,
A clearer path toward positive operating cash flow by late 2026,
Additional upside potential from zones not fully captured in prior reserve work.
The stock was hit hard on the broad uranium‑equity sell day, with intraday data showing a ~13% drop during regular trading as liquidity rotated out of higher‑beta names.
Why we remain bullish
The helium platform plus isotope‑enrichment portfolio (medical, quantum, and nuclear‑adjacent) offers differentiated, less‑correlated revenue streams versus pure uranium miners.
A credible timeline to positive cash flow from the Renergen project is a key inflection, shifting the story from purely developmental to self‑funding growth.
For investors who can tolerate volatility, we view pullbacks driven by sector risk‑off, rather than project setbacks, as opportunities to accumulate exposure to this advanced‑materials angle on the nuclear theme.
3. Oklo (OKLO)
Weekly action:
OKLO closed the week down from the low‑$80s, with a single‑day drop of about 7–8% as insider‑selling headlines and profit‑taking hit the name after a strong prior run.
What drove trading
The stock remains in digestion mode after the earlier January rally tied to its 1.2 GW nuclear campus agreement with Meta, Oklo’s first marquee commercial deal with a hyperscaler.
Trump’s Davos comments explicitly championing nuclear and SMRs kept policy optics favorable, but did not offset the impact from disclosed CEO and insider share sales totaling more than $100m over the prior months.
Liquidity‑driven selling and sentiment about valuation (pre‑revenue, large cap) outweighed fundamentals this week, leading to a sharp one‑day downdraft and a lower weekly close.
Why we remain bullish (with risk controls)
Oklo has now demonstrated real PPA traction with a top‑tier tech customer, a key de‑risking step for the SMR model in data‑center applications.
SMRs remain central to the U.S. strategy for dense, dispatchable power that can meet AI/data‑center load growth without overwhelming existing grid infrastructure.
We size exposure modestly given valuation and timeline risk, but continue to view pullbacks as opportunities to build positions for clients underwriting a 3‑5+ year horizon.
4. Centrus Energy (LEU)
Weekly action:
LEU traded choppy but essentially drifted lower versus recent highs, following a very strong move earlier in January after its $900m DOE task order; intraday historical data show sizable swings around the $280–310 area over the last stretch of trading days.
What drove trading
The market is still digesting the DOE contract to expand enrichment and HALEU capacity in Ohio, which was the primary driver of the earlier vertical move.
As focus shifted back to the broader uranium‑equity pullback late in the week, profit‑taking in LEU accelerated after its outsized January performance.
Commentary highlighting the stock’s sharp rally and valuation after the contract win also contributed to a more two‑sided tape.
Why we remain bullish
Centrus is uniquely positioned as the only U.S.‑owned commercial enricher, with both conventional LEU contracts (~$2.3b of commitments) and government‑backed HALEU build‑out.
Enrichment is a critical pinch‑point in the Western fuel cycle as utilities and governments move away from Russian services.
While we respect volatility and leverage, the combination of strategic importance, long‑term contracts, and federal support underpins our positive multi‑year view.
5. enCore Energy (EU)
Weekly action (US‑listing):
EU finished the week higher versus the prior Friday on the NASDAQ line, with daily closes stepping up from around the low‑$3.20s to the mid‑$3.60s–$3.70s range over the Jan 26–30 window.
What drove trading
U.S.‑focused ISR producers remained relative winners in the uranium complex as policy and security concerns kept domestic supply in focus.
Historical data show a strong month‑to‑date move, with EU up meaningfully over the past four weeks even after factoring in a small down‑day mid‑week as part of the sector shake‑out.
There were no negative company‑specific developments; flows appeared driven by continued rotation into liquid domestic producers and ETF demand.
Why we remain bullish
EU offers near‑term, scalable ISR production in the U.S., aligning directly with U.S. policy goals around domestic uranium supply and reduced dependence on Russian/Kazakh material.
The asset base (South Texas plus permitted projects like Dewey Burdock) provides a clear path to volume growth into a structurally tightening market.
We like EU as a core producer holding within the uranium sleeve, higher quality than many juniors but with more operating torque than the large diversified names.
Why We Stay Constructive Despite a Messy Tape
Across these names, this week’s pattern is consistent:
Fundamentals strengthened: uranium prices and contract terms moved higher; policy and AI/data‑center demand headlines stayed supportive.
Equities wobbled: selling pressure came mostly from profit‑taking, valuation debates, and positioning after a very strong January, not from negative company‑specific surprises.
We continue to view such weeks as accumulation opportunities for high‑conviction names across the fuel chain (production, enrichment, SMRs), especially where price has corrected more than fundamentals.
Track Our Positioning: SEQH Model Nuclear Fund
For clients and readers who want to follow how we’re actually expressing this theme, we run a dedicated Model Nuclear Fund that aggregates our best ideas across:
Uranium miners and developers
Fuel‑cycle infrastructure (conversion, enrichment, services)
Advanced nuclear / SMR and related technology plays
As a paid member of our research service, you can:
View current Model Nuclear Fund holdings and target weights
Get real‑time allocation and rebalance alerts
Access full write‑ups and ongoing thesis tracking across the nuclear complex
You can start a trial and become a paid member here to follow along with the Model Nuclear Fund and the rest of our research:
👉
